Phospholipid mass is increased in fibroblasts bearing the Swedish amyloid precursor mutation

Brain Research Bulletin

Volumn 69, Issue 1, 2006, Pages 79-85

  Murphy, Eric J ^a   Huang, Hsueh Meei ^b   Cowburn, Richard F ^c   Lannfelt, Lars ^d   Gibson, Gary E ^b  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer disease; Fibroblasts; Phospholipids; Plasmalogens; Swedish amyloid mutation

Indexed keywords

2 ACYL 1 ALKYLGLYCEROPHOSPHORYLETHANOLAMINE; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; CHOLINE DERIVATIVE; ETHANOLAMINE DERIVATIVE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PLASMALOGEN; PLASMANYLCHOLINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; MODEL; MUTATION; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; STEADY STATE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FIBROBLASTS; HUMANS; MUTATION; PHOSPHOLIPIDS; PLASMALOGENS;

EID: 31844438750     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2005.10.012     Document Type: Article

References (84)

1. D.K. Anderson, R.D. Saunders, P. Demediuk, L.L. Dugan, J.M. Braughler, E.D. Hall, E.D. Means, and L.A. Horrocks Lipid hydrolysis and peroxidation in injured spinal cord: partial protection with methylprednisolone or Vitamin E and selenium Central Nervous Syst. Trauma 2 1985 257 267
2. B. Begni, L. Brighina, E. Sirtori, L. Fumagalli, S. Andreoni, S. Beretta, T. Oster, C. Malaplate-Armand, V. Isella, I. Appollonio, and C. Ferrarese Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease Free Radic. Biol. Med. 37 2004 892 901
3. J.P. Blass, K.F. Sheu, S. Piacentini, and S. Sorbi Inherent abnormalities in oxidative metabolism in Alzheimer's disease: interaction with vascular abnormalities Ann. N. Y. Acad. Sci. 826 1997 382 385
4. J.K. Blusztajn, I.L. Gonzalez-Coviella, M. Logue, J.H. Growdon, and R.J. Wurtman Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients Brain Res. 536 1990 240 244
5. R.E. Bowman, and R.C. Wolf A rapid and specific ultramicro method for total serum cholesterol Clin. Chem. 8 1962 302 309
6. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
7. M. Brzyska, and D. Elbaum Dysregulation of calcium in Alzheimer's disease Acta Neurobiol. Exp. (Wars.) 63 2003 171 183
8. N.Y. Calingasan, K. Uchida, and G.E. Gibson Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease J. Neurochem. 72 1999 751 756
9. N. Cartier, J. Lopez, P. Moullier, F. Ricchiccioli, M.O. Rolland, P. Jorge, J. Mosser, J.L. Mandel, P.F. Bougneres, O. Danos, and P. Aubourg Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts Proc. Natl. Acad. Sci. U.S.A. 92 1995 1674 1678
10. C. Cecchi, C. Fiorillo, S. Sorbi, S. Latorraca, B. Nacmias, S. Bagnoli, P. Nassi, and G. Liguri Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients Free Radic. Biol. Med. 33 2002 1372 1379
11. S.L. Chan, M. Mayne, C.P. Holden, J.D. Geiger, and M.P. Mattson Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons J. Biol. Chem. 275 2000 18195 18200
12. K. Chandrasekaran, T. Giordano, D.R. Brady, J. Stoll, L.J. Martin, and S.I. Rapoport Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease Brain Res. Mol. Brain Res. 24 1994 336 340
13. K. Chandrasekaran, K. Hatanpaa, D.R. Brady, and S.I. Rapoport Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease Exp. Neurol. 142 1996 80 88
14. A.L. Cooper, K.F. Sheu, and J.P. Blass Normal glutamate metabolism in Alzheimer's disease fibroblasts deficient in alpha-ketoglutarate dehydrogenase complex activity Dev. Neurosci. 18 1996 499 504
15. D. Curti, F. Rognoni, L. Gasparini, A. Cattaneo, M. Paolillo, M. Racchi, L. Zani, A. Bianchetti, M. Trabucchi, S. Bergmaschi, and S. Govoni Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients Neurosci. Lett. 236 1997 13 16
16. +-ATPase, and lipid peroxidation In Vitro Cell. Dev. Biol. 21 1985 569 574
17. P. Demediuk, R.D. Saunders, D.K. Anderson, E.D. Means, and L.A. Horrocks Membrane lipid changes in laminectomized and traumatized cat spinal cord Proc. Natl. Acad. Sci. U.S.A. 82 1985 7071 7075
18. L.L. Dugan, P. Demediuk, C.E. Pendley II, and L.A. Horrocks Separation of phospholipids by high pressure liquid chromatography: all major classes including ethanolamine and choline plasmalogens, and most minor classes, including lysophosphatidylethanolamine J. Chromatogr. 378 1986 317 327
19. C. Edlund, M. Söderberg, K. Kristensson, and G. Dallner Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease Biochem. Cell Biol. 70 1992 422 428
20. A.A. Farooqui, S.I. Rapoport, and L.A. Horrocks Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens Neurochem. Res. 22 1997 523 527
21. A. Favit, M. Grimaldi, T.J. Nelson, and D.L. Alkon Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts Proc. Natl. Acad. Sci. U.S.A. 95 1998 5562 5567
22. T.A. Foglia, E. Nungesser, and W.N. Marmer Oxidation of 1-O-(alk-1-enyl)-2,3-di-O-acylglycerols: models for plasmalogen oxidation Lipids 23 1988 430 434
23. U.G. Fohr, G.E. Gibson, B. Tofel-Grehl, B.W. Schafer, and C.W. Heizmann Expression of intracellular calcium-binding proteins in cultured skin fibroblasts from Alzheimer and normal aged donors Biochim. Biophys. Acta 1223 1994 391 397
24. 2 during myocardial ischemia J. Clin. Invest. 88 1991 331 335
25. B.R. Fruen, and B.R. Lester Down's syndrome fibroblasts exhibit enhanced inositol uptake Biochem. J. 270 1990 119 123
26. B.R. Fruen, and B.R. Lester Inositol and inositol 1,4,5-triphosphate content in Down syndrome fibroblasts exhibiting enhanced inositol uptake FEBS Lett. 295 1991 43 47
27. G.E. Gibson, R. Martins, J. Blass, and S. Gandy Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients Life Sci. 59 1996 477 489
28. G.E. Gibson, L.C.H. Park, H. Zhang, S. Sorbi, N.Y. Calingasan, Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits, in: J.P. Blass, F.H. McDowell (Eds.), Mitochondrial/Energy Metabolism in Neurodegenerative Disorders, Ann. N. Y. Acad. Sci. 893 (1999) 79-94.
29. G.E. Gibson, B. Tofel-Grehl, K. Scheffold, V.J. Cristofalo, and J.P. Blass A reproducible procedure for primary culture and subsequent maintenance of multiple lines of human skin fibroblasts Age 21 1998 7 14
30. G.E. Gibson, M. Vestling, H. Zhang, S. Szolosi, D. Alkon, L. Lannfelt, S. Gandy, and R.F. Cowburn Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation Neurobiol. Aging 18 1997 573 580
31. G.E. Gibson, H. Zhang, L. Toral-Barza, S. Szolosi, and B. Tofel-Grehl Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease Biochim. Biophys. Acta 1316 1996 71 77
32. L. Ginsberg, J.R. Atack, S.I. Rapoport, and N.L. Gershfeld Regional specificity of membrane instability in Alzheimer's disease brain Brain Res. 615 1993 355 357
33. L. Ginsberg, S. Rafique, J.H. Xuereb, S.I. Rapoport, and N.L. Gershfeld Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain Brain Res. 698 1995 223 226
34. L. Ginsberg, J.H. Xuereb, and N.L. Gershfeld Membrane instability, plasmalogen content, and Alzheimer's disease J. Neurochem. 70 1998 2533 2538
35. S. Govoni, M. Racchi, S. Bergamaschi, M. Trabucchi, F. Battaini, A. Bianchetti, and G. Binetti Defective protein kinase C alpha leads to impaired secretion of soluble beta-amyloid precursor protein from Alzheimer's disease fibroblasts Ann. N. Y. Acad. Sci. 777 1996 332 337
36. X. Han, D.M. Holtzman, and D.W. McKeel Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry J. Neurochem. 77 2001 1168 1180
37. L.A. Horrocks, H.W. Harder, R. Mozzi, G. Goracci, E. Francescangeli, S. Porcellati, and G.G. Nenci Receptor mediated degradation of choline plasmalogen and glycerophospholipid methylation: a new hypothesis L. Freysz H. Dreyfus R. Massarelli S. Gatt Enzymes of Lipid Metabolism vol. 2 1986 Plenum Press New York 707 711
38. L.A. Horrocks, Y.K. Yeo, H.W. Harder, R. Mozzi, and G. Goracci Choline plasmalogens, glycerophospholipid methylation, and receptor-mediated activation of adenylate cyclase P. Greengard G.A. Robinson Advances in Cyclic Nucleotide Protein Phosphorylation Research vol. 20 1986 Raven Press New York 263 292
39. H.-M. Huang, and G.E. Gibson Altered β-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer's donors J. Biol. Chem. 268 1993 14616 14621
40. H.M. Huang, T.-A. Lin, G.Y. Sun, and G.E. Gibson Increased inositol 1,4,5-trisphosphate accumulation correlates with an up-regulation of bradykinin receptors in Alzheimer's disease J. Neurochem. 64 1995 761 769
41. + mobilization is altered in fibroblasts from patients with Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 91 1994 534 538
42. J.A. Johnston, R.F. Cowburn, S. Norgren, B. Wiehager, N. Venizelos, B. Winblad, C. Vigo-Pelfrey, D. Schenk, L. Lannfelt, and C. O'Neill Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer disease APP670/671 mutation FEBS Lett. 354 1994 274 278
43. S. Karmiol, and W.J. Bettger Accumulation of (n-9)-eicosatrienoic and docosatrienoic acids in human fibroblast phospholipids Lipids 23 1988 891 898
44. A. Kohlschutter, U.N. Wiesmann, N.N. Herschkowitz, and E. Ferber Phospholipid composition of cultivated skin fibroblasts in Duchenne's muscular dystrophy Clin. Chim. Acta 70 1976 463 465
45. C.M. Lauderback, J.M. Hackett, F.F. Huang, J.N. Keller, L.I. Szweda, W.R. Markesbery, and D.A. Butterfield The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42 J. Neurochem. 78 2001 413 416
46. M.A. Leissring, Y. Akbari, C.M. Fanger, M.D. Cahalan, M.P. Mattson, and F.M. LaFerla Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice J. Cell Biol. 149 2000 793 798
47. M.A. Lovell, C. Xie, and W.R. Markesbery Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures Free Radic. Biol. Med. 29 2000 714 720
48. J.F. Lu, A.M. Lawler, P.A. Watkins, J.M. Powers, A.B. Moser, H.W. Moser, and K.D. Smith A mouse model for X-linked adrenoleukodystrophy Proc. Natl. Acad. Sci. U.S.A. 94 1997 9366 9371
49. W.A. Maltese, and D.C. DeVivo Cholesterol and phospholipids in cultured skin fibroblasts from patients with dystonia Ann. Neurol. 16 1984 250 252
50. W.R. Markesbery, and M.A. Lovell Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease Neurobiol. Aging 19 1998 33 36
51. R.P. Mason, M.W. Trumbore, and J.W. Pettegrew Membrane interactions of a phosphomonoester elevated early in Alzheimer's disease Neurobiol. Aging 16 1994 531 539
52. 2 in cardiomyocytes Am. J. Physiol. 278 2000 H1933 H1940
53. 2 isoforms in cardiovascular pathophysiology Cardiovascular Toxicol. 1 2001 253 265
54. 2 activity in adult rat ventricular myocytes Am. J. Physiol. 272 1997 C450 C456
55. 2 in hypoxic ventricular myocytes Am. J. Physiol. 274 1998 C1727 C1737
56. K.S. Montine, E. Reich, M.D. Neely, K.R. Sidell, S.J. Olson, W.R. Markesbery, and T.J. Montine Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype J. Neuropathol. Exp. Neurol. 57 1998 415 425
57. O.H. Morand, R.A. Zoeller, and C.R.H. Raetz Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation J. Biol. Chem. 263 1988 11597 11606
58. E.J. Murphy, T.A. Rosenberger, and L.A. Horrocks Effects of maturation on the phospholipid and phospholipid fatty acid compositions in primary rat cortical astrocyte cell cultures Neurochem. Res. 22 1997 1205 1213
59. E.J. Murphy, R. Stephens, M. Jurkowitz-Alexander, and L.A. Horrocks Acidic hydrolysis of plasmalogens followed by high-performance liquid chromatography Lipids 28 1993 565 568
60. E.J. Murphy, H. Zhang, S. Sorbi, S.I. Rapoport, and G.E. Gibson Phospholipid composition and levels are not altered in fibroblasts bearing presenilin-1 mutations Brain Res. Bull. 52 2000 207 212
61. A. Netik, S. Forss-Petter, A. Holzinger, B. Molzer, G. Unterrainer, and J. Berger Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy Hum. Mol. Genet. 8 1999 907 913
62. R.M. Nitsch, J.K. Blusztajn, A.G. Pittas, B.E. Slack, J.H. Growdon, and R.J. Wurtman Evidence for a membrane defect in Alzheimer disease brain Proc. Natl. Acad. Sci. U.S.A. 89 1992 1671 1675
63. 2+]i-level of fibroblasts from Alzheimer patients and control individuals Neurochem. Res. 26 2001 817 820
64. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease J. Neuropathol. Exp. Neurol. 47 1988 235 248
65. M.J. Picklo Sr., T.J. Montine, V. Amarnath, and M.D. Neely Carbonyl toxicology and Alzheimer's disease Toxicol. Appl. Pharmacol. 184 2002 187 197
66. T.A. Rosenberger, J. Oki, A.D. Purdon, S.I. Rapoport, and E.J. Murphy Rapid synthesis and turnover of brain microsomal ether phospholipids in the adult rat J. Lipid Res. 43 2002 59 68
67. G. Rouser, A. Siakotos, and S. Fleischer Quantitative analysis of phospholipids by thin layer chromatography and phosphorus analysis of spots Lipids 1 1969 85 86
68. L.M. Sayre, D.A. Zelasko, P.L.R. Harris, G. Perry, R.G. Salomon, and M.A. Smith 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease J. Neurochem. 68 1997 2092 2097
69. D. Scheuner, C. Eckman, M. Jensen, X. Song, M. Citron, N. Suzuki, T.D. Bird, J. Hardy, M. Hutton, W. Kukull, E. Larson, E. Levy-Lahad, M. Viitanen, E. Peskind, P. Poorkaj, G. Schellenberg, R. Tanzi, W. Wasco, L. Lannfelt, D. Selkoe, and S. Younkin Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease Nat. Med. 2 1996 864 870 (see comments)
70. F. Schroeder, A. Frolov, J. Schoer, A. Gallegos, B.P. Atshaves, N.J. Stolwich, A.I. Scott, and A.B. Kier Intracellular cholesterol binding proteins, cholesterol transport, and membrane domains D. Freeman T.Y. Chang Intracellular Cholesterol Trafficking 1998 Kluwer Academic Publishers Boston 231 234
71. C. Shanahan, G.E. Gibson, R.F. Cowburn, J.A. Johnston, B. Wiehager, L. Lannfelt, and C. O'Neill G protein subunit levels in fibroblasts from familial Alzheimer's disease patients: lower levels of high molecular weight Gs alpha isoform in patients with decreased beta-adrenergic receptor stimulated cAMP formation Neurosci. Lett. 232 1997 33 36
72. H. Singh, K. Beckman, and A. Poulos Exclusive localization in peroxisomes of dihydroxyacetone phosphate acyltransferase and alkyl-dihydroxyacetone phosphate synthase in rat liver J. Lipid Res. 34 1993 467 477
73. I. Singh, O. Lazo, G.S. Dhaunsi, and M. Contreras Transport of fatty acids into human and rat peroxisomes. Differential transport of palmitic and lignoceric acids and its implication to X-adrenoleukodystrophy J. Biol. Chem. 267 1992 13306 13313
74. M. Söderberg, C. Edlund, I. Alafuzoff, K. Kristensson, and G. Dallner Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type J. Neurochem. 59 1992 1646 1653
75. M. Söderberg, C. Edlund, K. Kristensson, and G. Dallner Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease Lipids 26 1991 421 425
76. 2+ signals and altered membrane excitability J. Neurosci. 24 2004 508 513
77. L. Svennerholm, and C.G. Gottfries Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (Type I) and demyelination in late-onset form (Type II) J. Neurochem. 62 1994 1039 1047
78. G. Tesco, S. Latorraca, P. Piersanti, S. Piacentini, L. Amaducci, and S. Sorbi Alzheimer skin fibroblasts show increased susceptibility to free radicals Mech. Aging Dev. 66 1992 117 120
79. M. Vestling, A. Adem, M. Racchi, G.E. Gibson, L. Lannfelt, and R.F. Cowburn Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations Neuroreport 8 1997 2031 2035
80. M. Vestling, R.F. Cowburn, N. Venizelos, L. Lannfelt, B. Winblad, and A. Adem Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP670/671 mutation on binding levels J. Neural. Transm. Park. Dis. Dement. Sect. 10 1995 1 10
81. A. Wallin, C.G. Gottfries, I. Karlsson, and L. Svennerholm Decreased myelin lipids in Alzheimer's disease and vascular dementia Acta Neurol. Scand. 80 1989 319 323
82. K. Wells, A.A. Farooqui, L. Liss, and L.A. Horrocks Neural membrane phospholipids in Alzheimer disease Neurochem. Res. 20 1995 1329 1333
83. W.G. Wood, F. Schroeder, N.A. Avdulov, S.V. Chochina, and U. Igbauboa Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease Lipids 34 1999 225 234
84. R.A. Zoeller, O.H. Morand, and C.R.H. Raetz A possible role for plasmalogens in protecting animal cells against photosensitized killing J. Biol. Chem. 263 1988 11590 11596